baber/WOPTO huggingface dataset:
Patent NZ-551494-A (NZ)
Title: Fuel-fired dual tank water heater having dual pass condensing type heat exchanger
Inventor: MISSOUM OZZIE
Filed: 2006-08-25
Abstract: A fuel-fired commercial water heater (10) is disclosed. The fuel-fired commercial water heater (10) has upper and lower communicated tank portions (22, 24) which are separated by a plenum (26) forming a vertically intermediate portion of a dual pass condensing type heat exchanger (12). A lower portion of the heat exchanger (12) is defined by a series of vertical flue tubes (32) extending 10 through the lower tank (24) and intercommunicating the plenum (26) with a combustion chamber (30) disposed beneath the lower tank (24), and having a fuel burner (20) with a discharge portion communicated therewith. An upper portion of the heat exchanger (12) is defined by a vertical flue pipe (34), disposed in the upper tank (22), that extends upwardly from the plenum (26) and then coils downwardly around itself and horizontally 15 exits the upper tank (22). During firing of water heater (10) the burner (20) flows flue gases sequentially through the lower tank flue tubes (32), the plenum (26), and the upper tank coiled flue pipe structure (34).
Patent NZ-553468-A (NZ)
Title: 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
Inventor: DEANGELIS ALAN
IPC: A61K31/185
Filed: 2005-09-14
Abstract: Disclosed is a compound of Formula (I) wherein X is selected from a covalent bond, S and O; Y is S or O; Z is O of CH2, provided when Y is O then Z is O; and wherein the rest of the substituents are disclosed within the specification; or a pharmaceutically acceptable salt thereof. Also disclosed is the use of a compound of Formula (I) in the preparation of a medicament for treating or inhibiting the progression of a PPAR-delta mediated condition.
Patent NZ-564058-A (NZ)
Title: Bovine thrombin purification
Inventor: PAWLAK DAN
IPC: A61K38/00
Filed: 2006-05-25
Abstract: Disclosed is a method for the preparation of a purified bovine thrombin composition, substantially free of impurities having a molecular weight greater than 40 kDa, and having a specific activity greater than 1800 units of thrombin per mg (u/mg) of protein, which method comprises: (a) applying a bovine thrombin preparation having from about 500 to about 3000 units of thrombin per mL (u/mL) of the preparation to a cation exchange chromatography to afford a pre-purified bovine thrombin composition having a specific activity greater than about 1500 u/mg of protein; (b) applying the pre-purified bovine thrombin composition from step (a) to a size exclusion filtration capable of excluding impurities having a molecular weight greater than 40 kDa to afford a purified bovine thrombin composition, substantially free of impurities having a molecular weight greater than 40 kDa, and having a specific activity greater than 1800 u/mg of protein; and optionally, (c) applying the purified bovine thrombin composition from step (b) to an anion exchange filtration.
Patent NZ-571048-A (NZ)
Title: Automatic system for guiding, retaining and tightening steel wire rope in cranes
Inventor: TAVIO DIAZ MIGUEL ANGEL
IPC: B66C13/20
Filed: 2006-07-20
Abstract: Disclosed is an automatic system for guiding, retaining and tightening steel wire ropes in cranes, characterized in that it comprises: at least two self-blocking clamps per rope positioned to engage the rope at spaced apart intervals; at least one tightening element that engages each rope at a position between said self-blocking clamps; and sheaves for guiding the ropes between said self-blocking clamps and said tightening element. The system is based on a wedge mechanism that allows automatic and instantaneous (remotely controlled) actuation. The system makes it possible to carry out a cable-change operation with the boom raised, thus allowing manoeuvring of vessels and operation of nearby cranes; it also reduces cable-replacement times; and allows the use of the clamps and tightening element as a mechanism for adjusting the length of the branches. Spreader misalignments can be instantaneously corrected.
Patent NZ-571185-A (NZ)
Title: An improved blank and an assembly for a coffin
Inventor: KEMMERER ECKHARD
IPC: A61G17/007
Filed: 2008-09-12
Abstract: A blank for a coffin comprising a blank body (12) defining a plurality of wall panels (14, 16, 18, 20) each having a dedicated pair of opposed sides; a base supporting member (28) formed integrally with one side of at least one of the panels; and a flap member (30) formed integrally with the opposite side of at least certain of the panels, where the base supporting member is foldable, substantially at right angles to its panel, to form a ledge on which the base is receivable. The blank is formed from a sandwich structured composite comprising a core sandwiched between a pair of flexible liners. (61) Addition to 555925
Patent NZ-573031-A (NZ)
Title: Compounds for the treatment of metabolic disorders
Inventor: SHARMA SHALINI
IPC: A61K31/66
Filed: 2007-06-08
Abstract: Disclosed is 3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid as pictured. Also disclosed is a pharmaceutical composition comprising the compound and the use of 3-(2,4-Bis(trifluoromethyl)benzyloxy) phenylacetic acid or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment of a condition selected from the group consisting of insulin resistance syndrome, diabetes including Type I Diabetes and Type II Diabetes, and polycystic ovary syndrome; or for the treatment or reduction in the chance of developing atherosclerosis, arteriosclerosis, obesity, hypertension, hyperlipidaemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration or cataracts associated with diabetes; or for the treatment of a condition selected from the group consisting of hyperlipidaemia, cachexia, and obesity.
Patent NZ-582011-A (NZ)
Title: Isolated polynucelotide encoding a non-ethylene binding ethylene receptor polypeptide
Inventor: GALLIE DANIEL R
IPC: C12N15/82
Filed: 2008-07-18
Abstract: Disclosed is an isolated polynucleotide encoding a non-ethylene binding ethylene receptor polypeptide, wherein: (a) the non-ethylene binding ethylene receptor polypeptide comprises a sequence at least 95% identical to SEQ ID NO:6 wherein the amino acid at position 102 is not a cysteine; and (b) expression of the non-ethylene binding ethylene receptor polypeptide results in a staygreen phenotype in a plant. Also disclosed is a method of reducing ethylene sensitivity in a plant.
Patent NZ-583819-A (NZ)
Title: Polymer comprising a dicarboxy-derivatised chitosan polymer cross-linked to an aldehyde-derivatised dextran polymer useful for preventing tissue adhesion and for promoting wound healing
Inventor: ATHANASIADIS THEODORE
IPC: A61P17/02
Filed: 2008-08-26
Abstract: Disclosed is a composition comprising dicarboxy-derivatised chitosan polymer cross-linked to an aldehyde-derivatised dextran polymer. N-succinyl chitosan is a preferred dicarboxy group to derivitise chitosan. The composition is in the form of a hydrogel that can be applied to surgical and other wounds. The composition assists in wound healing and helps prevent adhesions forming between neighbouring tissues that have been damaged.
Patent NZ-588013-A (NZ)
Title: Device for improved delivery of gas to fluid comprises an outer frustom with an internal helically cut cone
Inventor: BURNS DAVID
IPC: C02F1/78
Filed: 2009-02-23
Abstract: 588013 A device 1 for diffusion of gas into liquid comprises an outer housing of hollow frustum shape having a central axis that extends from a small diameter liquid outlet end 12 defining a liquid outlet opening to a large diameter end 18. A liquid inlet port is formed in the housing for delivery of liquid into the hollow housing. A helically cut cone 16 having an inner curvature is positioned and affixed within the hollow centre of the housing with its axis aligned with that of the hollow frustum shape such that liquid delivered into the housing forms a swirling motion around the outside of the member as it passes from inlet to outlet. The housing has a gas inlet 14 for delivery of gas to the liquid within the housing as it moves from the inlet to the outlet opening.
Patent NZ-589270-A (NZ)
Title: Multiple myeloma treatments
Inventor: OCIO ENRIQUE
IPC: A61K33/243
Filed: 2009-05-18
Abstract: Provided is the use of PM00104 (shown in Formula (I), an alkaloid related to jorumycin and renieramycins,and also to safracin and saframycin compounds), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of multiple myeloma.
Patent NZ-591802-A (NZ)
Title: Oral and personal care compositions and methods
Inventor: BOYD THOMAS J
IPC: A61K8/26
Filed: 2004-12-16
Abstract: Provided is a personal care composition comprising a carrier having distributed therein a plurality of lamellar fragments, wherein said fragments comprise a matrix and a functional material comprising at least one of a therapeutic active and a flavourant, wherein said carrier is suitable for use in an oral care composition, hair care composition, skin care composition, or deodorant composition and wherein said matrix comprises a film forming material selected from the group consisting of water soluble polymers, water dispersible polymers, water insoluble polymers, and mixtures thereof. Specific fragment thicknesses, lengths and aspect ratios are also provided.
Patent NZ-592278-A (NZ)
Title: mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY
Inventor: ELSNER JAN
IPC: A61P35/00
Filed: 2009-10-27
Abstract: Disclosed is a compound having formula (II) e.g. 7-(6-(1H-1 ,2,4-triazol-3-yl)pyridin-3-yl)-1-( cis-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein R1, R2 and R3 are defined in the specification for treating multiple myeloma, mantle cell lymphoma, diffused large B-cell lymphoma, acute myeloid lymphoma, follicular lymphoma, chronic lymphocytic leukemia; breast, lung, endometrial, ovarian, gastric, cervical, or prostate cancer; glioblastoma; renal carcinoma; hepatocellular carcinoma; colon carcinoma; neuroendocrine tumors; head and neck tumors; sarcomas; tumor syndromes resulting directly or indirectly from genetic defects in PTEN, TSC1, TSC2, NFl, AMPK, LKB1, VHL or PKD1; Cowden's disease, Cowden syndrome, Cowden-like syndrome, Bannayan-Zonana syndrome, Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease, endometrial carcinoma, tuberous sclerosis complex, lymphangioleiomyomatosis, neurofibromatosis 1, Peutz-Jeghers syndrome, renal cell carcinoma, von Hippel-Lindau disease, Proteus syndrome, or polycystic kidney disease; rheumatoid arthritis; rheumatoid spondylitis; osteoarthritis; gout; asthma, bronchitis; allergic rhinitis; chronic obstructive pulmonary disease; cystic fibrosis; inflammatory bowel disease; irritable bowel syndrome; mucous colitis; ulcerative colitis; Crohn' s disease; Huntington's disease; gastritis; esophagitis; hepatitis; pancreatitis; nephritis; multiple sclerosis; lupus erythematosus; atherosclerosis; restenosis following angioplasty; left ventricular hypertrophy; myocardial infarction; stroke; ischemic damages of heart, lung, gut, kidney, liver, pancreas, spleen and brain; acute or chronic organ transplant rejection; preservation of the organ for transplantation; organ failure or loss of limb; graft versus host disease; endotoxin shock; multiple organ failure; psoriasis; bum from exposure to fire, chemicals or radiation; eczema; dermatitis; skin graft; ischemia; ischemic conditions associated with surgery or traumatic injury; epilepsy; Alzheimer's disease; Parkinson's disease; immunological response to bacterial or viral infection; cachexia; angiogenic or proliferative diseases.
Patent NZ-594128-A (NZ)
Title: Dosing device with a strip tape display indicating fill level
Inventor: VON SCHUCKMANN ALFRED
IPC: G01F11/24
Filed: 2009-12-28
Abstract: A dosing device (1) for inhaling a powdery substance (2) is disclosed. The powder (2) is arranged in a storage chamber (6) above a trailing bottom (7) and can be brought from the storage chamber into a readiness position. A display is associated with the actual filling level in the area of a transparent device wall (18). The display is composed of a strip tape (19) carried by the bottom (7) and deflected by 180 DEGREE where the deflection area of the strip tape (19) lies behind the transparent device wall (18).
Patent NZ-595206-A (NZ)
Title: Prodrug forms of kinase inhibitors and their use in therapy
Inventor: SMAILL JEFFREY BRUCE
IPC: A61P35/00
Filed: 2010-03-11
Abstract: 595206 Disclosed herein are prodrug compounds comprising a kinase inhibitor and a reductively-activated fragmenting aromatic nitroheterocycle or aromatic nitrocarbocycle trigger, where the compound carries a positive charge. In preferred embodiments, the trigger has the structure of Formula IIId wherein * is a point of attachment, R8 is selected from H and C1–C3 alkyl, and R9 is selected from H and C1–C6 alkyl. The disclosed compounds are useful in treating proliferative diseases such as cancer.
Patent NZ-598002-A (NZ)
Title: Damper apparatus
Inventor: CONTARINO ALDO
IPC: B60G13/04
Filed: 2012-02-01
Abstract: 598002 A damper apparatus 10 comprising a housing 12, an inner member 14 and a damper material 16 interposed in between, the damper material 16 being bonded to both the housing 12 and the inner member 14 member, such that substantially the entire surface of the damper material 16 facing the inner member 14 is bonded to the inner member 14, where at least one of the housing 12 and the inner member 14 is able to rotate or be rotated relative to the other in a substantially concentric manner, and at least the inner member 14 is provided in a form or configuration presenting a limited torque angle to the damper material 16. The form or configuration comprises two or more lobes 30 projecting from a centre of the inner member. Each lobe 30 is rounded in general form and has a smooth transition extending between adjacent lobes. This design may prevent the damper material 16 breaking down through shearing forces induced there in use, or through the damper material 16 being forced/extruded outwardly/laterally, or being caused to bulge, from its housing.
Patent NZ-602026-A (NZ)
Title: Cheese with enhanced organoleptic and melting properties
Inventor: HORAN KATHRYN J
IPC: A23C19/00
Filed: 2012-08-24
Abstract: NZ 602026 Disclosed is a cheese product comprising a mixture of natural cheese other than cream cheese and cream cheese powder in an amount of about 1 % to about 15% by weight of the cheese product, the cream cheese powder including from about 60% to about 70% total fat, from about 8% to about 10% protein, from about 13% to about 16% total carbohydrates, and a moisture content of up to about 10%, wherein the cream cheese powder is incorporated into a physical structure of the natural cheese and is not visible on an exterior surface of the natural cheese. Also disclosed is a method of making a cheese product, the method comprising the steps of: preparing a natural cheese curd other than a cream cheese curd; adding cream cheese to the natural cheese curd at a temperature of less than 100°F and stirring the natural cheese curd and the cream cheese together to obtain a mixture including cream cheese in an amount of about 1 % to about 15% of total weight; and pressing the mixture to form the cheese product.
Patent NZ-603990-A (NZ)
Title: Biotechnological production of chondroitin
Inventor: DALY SIMONA
IPC: A61K31/737
Filed: 2011-06-01
Abstract: Disclosed is a recombinant microorganism producing chondroitin, defined as a linear glycosaminoglycan constituted by alternating residues of D-glucuronic acid (GlcUA) and N-acetyl-D-galactosamine (GalNAc) bound by beta-1-3 (GlcUA to GalNAc) and beta-1-4 (GalNAc to GlcUA) bonds, characterised in that in said microorganism the kfoE gene originally present which encodes an enzyme responsible for the addition of fructose residues to the linear chondroitin backbone is inactivated by deletion or substitution entirely or in part of said gene or disruption by insertion of an additional nucleotide sequence and wherein said kfoE gene encodes a protein selected from the group consisting of: a protein comprising the amino acid sequence of SEQ ID No: 2 (as defined in the specification); a protein comprising the amino acid sequence of SEQ ID No: 2 (as defined in the specification) modified by deletion, substitution, or insertion of one or more amino acids, and having a fructosyl-transferase activity; and a protein comprising an amino acid sequence having homology of at least 50% with the amino acid sequence of SEQ ID No: 2 (as defined in the specification) and having a fructosyl-transferase activity.
Patent NZ-614857-A (NZ)
Title: Bispecific antibodies and methods for production thereof
Inventor: LABRIJN ARAN FRANK
IPC: C07K16/46
Filed: 2008-03-28
Abstract: Disclosed is an isolated bispecific antibody comprising two IgG4-like CH3 regions, wherein the sequences outside the core hinge region and outside the CH3 region are of an isotype selected from the group consisting of IgG1, IgG2 and IgG3, and wherein the IgG4-like CH3 region does not form stable inter-half-molecule interactions when tested by replacing the CH3 of an IgG4 with the IgG4-like CH3 region and exchange is observed in the presence of a reducing agent. Also disclosed is an ex vivo method for the generation of a bispecific antibody, said method comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody, wherein the sequences of the first and/or second antibody outside the core hinge region and outside the CH3 region are of an isotype selected from the group consisting of IgG1, IgG2 and IgG3, and wherein the IgG4-like CH3 region does not form stable inter-half-molecule interactions when tested by replacing the CH3 of an IgG4 with the IgG4-like CH3 region and exchange is observed in the presence of a reducing agent.
Patent NZ-616479-A (NZ)
Title: Complement factor b analogs and their uses
Inventor: CHEN CHANGHUNG
IPC: A61K39/395
Filed: 2012-05-04
Abstract: Discloses a polypeptide comprising a complement factor B protein analogue, wherein the complement factor B analogue comprises a mutation of a free cysteine amino acid and is at least 90% identical to amino acids 26-764 of SEQ ID NOs: 1, 2 or 3; to amino acids 26-990 of SEQ ID NOs:22 or 23; to amino acids 26-480 of SEQ ID NO:2; or to amino acids 26-1003 of SEQ ID NO:26, wherein the sequences are as defined in the complete specification, and related methods, nucleic acids and vectors. These are used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
Patent NZ-619408-A (NZ)
Title: Compositions and methods for prophylaxis and treatment of addictions
Inventor: CICCOCIOPPO ROBERTO
IPC: A61P25/36
Filed: 2010-03-11
Abstract: The present disclosure relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPAR) agonist in combination with another therapeutic agent, specifically an opioid agonist, for preventing or reducing the likelihood that a subject will develop analgesic tolerance to the opioid agonist, wherein the opioid agonist is selected from the group consisting of codeine, diacetylmorphine (heroin), dihydrocodeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, papaverine, remifentanil, sufentanil, and tramadol, or any combination thereof.
Patent NZ-700273-A (NZ)
Title: Negative example (anti-word) based performance improvement for speech recognition
Inventor: GANAPATHIRAJU ARAVIND
IPC: G10L15/26
Filed: 2013-04-26
Abstract: A system and method are presented for negative example based performance improvements for speech recognition. The presently disclosed embodiments address identified false positives and the identification of negative examples of keywords in an Automatic Speech Recognition (ASR) system. Various methods may be used to identify negative examples of keywords. Such methods may include, for example, human listening and learning possible negative examples from a large domain specific text source. In at least one embodiment, negative examples of keywords may be used to improve the performance of an ASR system by reducing false positives.
Patent NZ-703190-A (NZ)
Title: A measuring instrument for use in orthopaedic surgery
Inventor: REEVE MICHAEL
IPC: A61F2/46
Filed: 2013-05-24
Abstract: A measuring instrument (2) for use during an orthopaedic surgical procedure to measure first and second distances from a reference point on a bone to first and second measurement points respectively. The measuring instrument has a first scale (24) for displaying the first distance and a second scale (28) for displaying the second distance. It includes a mask (26) which can be positioned against the second scale after the first distance has been measured in a position that is selected relative to the second scale dependent on the measured first distance, to restrict the length of the second scale that is visible to the user.
Patent NZ-731172-A (NZ)
Title: Automated exchange of healthcare information for fulfillment of medication doses
Inventor: PADMANI BHAVESH S
IPC: G16H10/60
Filed: 2015-10-26
Abstract: Automated healthcare information exchange. The healthcare information may comprise one or more dose orders corresponding to dose medications to be administered to a patient. The healthcare information may be received (e.g., from an EMR system such as a hospital information system (HIS) or the like) in the form of a healthcare information data stream. The information may then be standardized in to a standardized intermediate form. For instance, data may be parsed from the data stream and used to populate a staging table. In turn, data from the staging table may be transformed into an input format specific to a given dose fulfillment client to which the dose order is provided for fulfillment of the dose. Additionally, exception processing. logistical processing, and management functionality may be applied to the dose orders.
Patent NZ-747372-A (NZ)
Title: Combustion-powered fastener driving tool fuel cell assembly
Inventor: CRAWFORD RONALD BRETT
IPC: F17C13/04
Filed: 2017-05-10
Abstract: Various embodiments of the present disclosure provide a combustion-powered fastener driving tool fuel cell assembly including a fuel cell (100), fuel cell adapter (200), and fuel cell adapter cap (300) for a combustion-powered fastener driving tool. The fuel cell, the fuel cell adapter, and the fuel cell adapter cap enable both the fuel cell adapter (200) and the fuel cell adapter cap (300) to be attached to a fuel cell (100) and particularly a sealing member (130) of the fuel cell in one efficient step. This single step process can be done manually or automatically, and is substantially more efficient and less time-consuming than the known fuel cell assemblies.